碩世生物(688399.SH):選舉王國強為董事長
格隆匯9月19日丨碩世生物(688399.SH)公佈,公司第三屆董事會成員已經2023年第一次臨時股東大會選舉產生。根據《公司法》、《公司章程》的規定,董事會選舉王國強先生擔任公司第三屆董事會董事長,任期於本議案通過之日起至本屆董事會任期屆滿之日止。
本屆董事會換屆後,房永生先生不再擔任公司董事長,房永生先生目前擔任公司董事、戰略委員會主任委員、薪酬與考核委員會委員職務,作為公司實際控制人之一,核心的領軍人物,房永生先生帶領公司堅持創新,使公司不斷髮展壯大併成功在上海證券交易所科創板上市,董事會同意聘任房永生先生擔任公司名譽董事長,任期與第三屆董事會任期一致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.